XENE Xenon Pharmaceuticals Inc.

9.33
-0.48  -5%
Previous Close 9.81
Open 9.89
Price To Book 2.52
Market Cap 240259312
Shares 25,751,266
Volume 96,926
Short Ratio
Av. Daily Volume 91,286

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b data due 2H 2020.
XEN1101
Adult focal seizures
Phase 2 data released March 24, 2017 - endpoints not met.
XEN801
Acne
Phase 2b data released June 27, 2017. Endpoints not met.
TV-45070
Postherpetic neuralgia
Phase 2b trial did not meet endpoints - July 2015
TV-45070
Osteoarthritis
IND filing has been accepted - noted January 28, 2019.
XEN1101
Epilepsy
Phase 2 trial to be initiated 2019.
XEN901
Pediatric epilepsy
Phase 3 trial to be initiated following IND filing 3Q 2019.
XEN496
Epilepsy

Latest News

  1. Edited Transcript of XENE earnings conference call or presentation 6-Mar-19 9:30pm GMT
  2. Xenon Pharmaceuticals Reports 2018 Financial Results and Provides Corporate Update
  3. Xenon Pharmaceuticals Inc. to Host Earnings Call
  4. The Daily Biotech Pulse: Horizon Pharma Under DoJ Radar, FDA Greenlights J&J's Depression Drug, Endologix Reverse Split
  5. Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss 2018 Financial Results and Provide Corporate Update
  6. Behind the Seizure™ Program Expansion Helps Speed the Diagnosis of Genetic Epilepsy in Younger Children Experiencing Unprovoked Seizures
  7. Xenon Provides Key Regulatory Updates on XEN007 and XEN1101
  8. What Kind Of Shareholder Owns Most Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Stock?
  9. Xenon Pharmaceuticals Outlines 2019 Key Milestones
  10. Eversept Partners’ Return, AUM, and Holdings
  11. Xenon Pharmaceuticals Inc (XENE): Are Hedge Funds Right About This Stock?
  12. Xenon Announces Final Results of XEN1101 Phase 1 Clinical Trial and Update on XEN901 Phase 1 Clinical Trial at the American Epilepsy Society (AES) Annual Meeting
  13. Xenon Pharmaceuticals to Host Conference Call and Webcast to Provide Corporate Update and Overview of Presentations at the 2018 American Epilepsy Society (AES) Meeting
  14. Edited Transcript of XENE earnings conference call or presentation 6-Nov-18 9:30pm GMT
  15. Granite Point Capital’s Returns, AUM, and Holdings
  16. Is Xenon Pharmaceuticals Inc (NASDAQ:XENE) Overpaying Its CEO?
  17. Investor Expectations to Drive Momentum within The York Water, Canon, Peak Resorts, Volt Information Sciences, LSI Industries, and Xenon Pharmaceuticals — Discovering Underlying Factors of Influence
  18. Xenon Pharmaceuticals to Present at the Stifel 2018 Healthcare Conference
  19. Xenon Pharmaceuticals: 3Q Earnings Snapshot
  20. Xenon Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update